FindTrial
Sign In

LEO 90100 aerosol foam

DRUG6 trials

Sponsors

LEO Pharma

Conditions

Psoriasis VulgarisSkin and Connective Tissue Diseases

Phase 1

Vasoconstriction Trial With LEO 90100 Aerosol Foam
CompletedNCT02973776
LEO PharmaPsoriasis Vulgaris
Start: 2016-12-31End: 2017-02-28Updated: 2017-05-09

Phase 2

A Psoriasis Plaque Test Trial With LP0113 Spray in Patients With Psoriasis Vulgaris (LP0113-1123)
CompletedNCT02416258
LEO PharmaSkin and Connective Tissue Diseases
Start: 2015-04-30End: 2015-06-30Updated: 2025-02-24
A Psoriasis Plaque Test Trial With LEO 90100 Compared to Betesil® in Patients With Psoriasis Vulgaris
CompletedNCT02518048
LEO PharmaSkin and Connective Tissue Diseases
Start: 2015-08-31End: 2016-01-31Updated: 2025-03-10

Phase 3

LEO 90100 Aerosol Foam Compared to Calcipotriol Plus Betamethasone Dipropionate Gel in Subjects With Psoriasis Vulgaris
CompletedNCT02132936
LEO PharmaPsoriasis Vulgaris
Start: 2014-06-30End: 2015-02-28Updated: 2025-03-10
Patient Insights Following Use of LEO 90100 Aerosol Foam and Daivobet® Gel in Subjects With Psoriasis Vulgaris
CompletedNCT02310646
LEO PharmaPsoriasis Vulgaris
Start: 2015-01-31End: 2015-07-31Updated: 2025-03-10
LEO 90100 Twice Weekly Maintenance Regimen for Psoriasis Vulgaris
CompletedNCT02899962
LEO PharmaPsoriasis Vulgaris
Start: 2017-02-15End: 2019-06-26Updated: 2020-08-20

Related Papers

Matching-Adjusted Indirect Comparison of Long-Term Efficacy and Safety Outcomes for Calcipotriol Plus Betamethasone Dipropionate Foam Versus Halobetasol Proprionate Plus Tazarotene Lotion in the Treatment of Plaque Psoriasis.
2022-10-123 citations
Impact of fixed‐dose combination Cal/BD foam on the work productivity of patients with psoriasis: results from the 52‐week randomized, double‐blind, PSO‐LONG trial
Journal of the European Academy of Dermatology and Venereology2022-03-174 citations
Long-Term Proactive Treatment of Plaque Psoriasis with Calcipotriene/Betamethasone Dipropionate Foam Prolongs Remission and Reduces Relapses Irrespective of Patient Baseline Characteristics.
2021-08-024 citations
Clinical, patient and estimated cost benefits of proactive management versus reactive management with calcipotriol/betamethasone dipropionate foam for the treatment of plaque psoriasis in Finland.
2021-07-073 citations
Calcipotriene Plus Betamethasone Dipropionate Foam for Mild Psoriasis: Pooled Results from Three Randomized Trials
Journal of Drugs in Dermatology2021-07-011 citations
PSO-LONG: Design of a Novel, 12-Month Clinical Trial of Topical, Proactive Maintenance with Twice-Weekly Cal/BD Foam in Psoriasis
Advances in Therapy2020-09-238 citations
Twice-weekly topical calcipotriene/betamethasone dipropionate foam as proactive management of plaque psoriasis increases time in remission and is well tolerated over 52 weeks (PSO-LONG trial).
2020-09-1839 citations
Calcipotriol/Betamethasone Dipropionate Cutaneous Foam Treatment for Psoriasis in Patients With BSA 5-15% and PGA ≥ 3: Post-Hoc Analysis From Three Randomized Controlled Trials.
2020-08-123 citations
PGAxBSA composite versus PASI: Comparison across disease severities and as therapeutic response measure for Cal/BD foam in plaque psoriasis.
2020-05-169 citations
Itch relief in patients with psoriasis: effectiveness of calcipotriol plus betamethasone dipropionate foam
Journal of the European Academy of Dermatology and Venereology2018-12-0623 citations
Patients with psoriasis have different preferences for topical therapy, highlighting the importance of individualized treatment approaches: randomized phase IIIb PSO-INSIGHTFUL study.
2017-09-1431 citations
Calcipotriol Plus Betamethasone Dipropionate Aerosol Foam in Patients with Moderate-to-Severe Psoriasis: Sub-Group Analysis of the PSO-ABLE Study.
2017-06-0122 citations
Efficacy and Safety of Calcipotriol Plus Betamethasone Dipropionate Aerosol Foam Compared with Betamethasone 17-Valerate-Medicated Plaster for the Treatment of Psoriasis.
2017-04-019 citations
Calcipotriol plus betamethasone dipropionate aerosol foam provides superior efficacy vs. gel in patients with psoriasis vulgaris: randomized, controlled PSO-ABLE study.
2016-08-1780 citations